📊 GTBP Key Takeaways
Is GTBP a Good Investment? Thesis Analysis
GT Biopharma is a pre-revenue pharmaceutical company experiencing severe financial distress with $12.9M annual cash burn against only $6.8M in cash reserves, creating a 6-month operational runway. Despite marginal improvement in losses year-over-year, zero revenue generation, total absence of capital investment, and negative ROE/ROA of -490%/-349.8% indicate fundamental business viability failure.
Why Buy GTBP? Key Strengths
- Strong liquidity position with 3.50x current ratio and $6.8M cash on hand
- Zero debt burden provides financial flexibility and avoids bankruptcy risk from leverage
- Improving net loss trend with 17.7% YoY improvement reducing operating burn
GTBP Investment Risks to Consider
- Zero revenue generation indicating complete failure to commercialize products or execute business model
- Cash runway of only ~6 months at current burn rate of $12.9M annually
- Severely negative returns on equity (-490%) and assets (-349.8%) destroying shareholder value
- No capital expenditure or R&D investment visible suggesting stalled product development
- Deeply negative EPS of -$6.68 per share unsustainable long-term
- Zero insider buying activity in 90 days indicates no management confidence in recovery
Key Metrics to Watch
- Monthly cash burn rate and remaining liquidity runway
- Revenue initiation or clinical trial milestone announcements
- Operating cash flow stabilization or improvement
- Debt issuance or equity raise announcements indicating survival financing needs
GTBP Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 3.50x current ratio provides a solid financial cushion.
GTBP Profitability Ratios
GTBP vs Healthcare Sector
How GT Biopharma, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is GTBP Overvalued or Undervalued?
Based on fundamental analysis, GT Biopharma, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
GTBP Balance Sheet & Liquidity
GTBP 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: GT Biopharma, Inc.'s revenue has declined by 100% over the 5-year period, indicating business contraction. The most recent EPS of $-6.94 indicates the company is currently unprofitable.
GTBP Growth Metrics (YoY)
GTBP Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2021 | N/A | $1.9M | N/A |
| Q2 2021 | N/A | $1.6M | N/A |
| Q1 2021 | N/A | -$1.7M | N/A |
| Q1 2020 | N/A | -$1.7M | $-0.02 |
| Q1 2019 | N/A | -$4.5M | $-0.09 |
| Q2 2018 | N/A | -$2.5M | $335,450.00 |
| Q1 2018 | N/A | -$5.1M | $-0.20 |
| Q3 2017 | N/A | -$3.6M | $-8.24 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
GTBP Capital Allocation
GTBP SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for GT Biopharma, Inc. (CIK: 0000109657)
📋 Recent SEC Filings
❓ Frequently Asked Questions about GTBP
What is the AI rating for GTBP?
GT Biopharma, Inc. (GTBP) has an AI rating of STRONG SELL with 88% confidence, based on fundamental analysis of SEC EDGAR filings.
What are GTBP's key strengths?
Claude: Strong liquidity position with 3.50x current ratio and $6.8M cash on hand. Zero debt burden provides financial flexibility and avoids bankruptcy risk from leverage.
What are the risks of investing in GTBP?
Claude: Zero revenue generation indicating complete failure to commercialize products or execute business model. Cash runway of only ~6 months at current burn rate of $12.9M annually.
What is GTBP's revenue and growth?
GT Biopharma, Inc. reported revenue of $0.0.
Does GTBP pay dividends?
GT Biopharma, Inc. pays dividends, with $0.2M distributed to shareholders in the trailing twelve months.
Where can I find GTBP SEC filings?
Official SEC filings for GT Biopharma, Inc. (CIK: 0000109657) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is GTBP's EPS?
GT Biopharma, Inc. has a diluted EPS of $-6.68.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is GTBP a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, GT Biopharma, Inc. has a STRONG SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is GTBP stock overvalued or undervalued?
Valuation metrics for GTBP: ROE of -490.0% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy GTBP stock in 2026?
Our dual AI analysis gives GT Biopharma, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is GTBP's free cash flow?
GT Biopharma, Inc.'s operating cash flow is $-12.9M, with capital expenditures of $0.0.
How does GTBP compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -490.0% (avg: 15%), current ratio 3.50 (avg: 2).